The Role of CAR T Cells in Human Health and Disease
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 854
Special Issue Editor
2. German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
Interests: tumor antigens; peptide vacation; cell therapy; CAR T cells; TCR T cells; tolerance induction
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the last 5 years, chimeric antigen receptor (CAR) T cells became a standard clinical treatment option for patients with CD19+ leukemia and lymphoma, as well as for BCMA+ multiple myeloma. They are currently used in 2500 patients per year in Europe and 25,000 patients in the USA. Response rates are high (80–100%) but after 3 years, only 10–20% of adult leukemia and 40% of adult lymphoma patients are still free from relapse. Side effects like immune-cell-associated neuropathy syndrome (ICANS), cytokine release syndrome (CRS) and hematotoxicity vary from product to product.
Therefore, there is a lot of room for improvement. In current research, there exist promising approaches with novel target cancer antigens, multi-antigen targeting, enhancement of CAR T cells by novel vector constructs like TRUCKs, cytokines like IL-15, inhibition of nocious interaction of other immune cells like NK cells and MDSC cells with CAR T cells. Combination approaches of CAR T cells with peptide, protein or mRNA vaccines in the mouse model as well as in clinical studies will be of highest interest. Non-viral approaches like transposons, minicircles, nanoplasmids, etc., will be highly appreciated.
Last, but not least, gene editing of genes improving CAR T cell function and interaction with other players of the immune system will open new avenues towards our goal to make CAR T cell therapy even more safe and effective.
The present Special Issue aims to provide a broad overview on all the above-mentioned fields of research and development in current CAR T cell therapy. I am looking forward to your upcoming submissions.
Prof. Dr. Michael Schmitt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T cells
- vector design
- combined vaccination and CAR T cell therapy
- non-viral transductioin
- genetic engineering
